The effect of COVID-19 on Multiple Sclerosis relapse: A systematic review and meta-analysis

Wallin, 2019, Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol., 18, 269, 10.1016/S1474-4422(18)30443-5 Correale, 2006, The risk of relapses in multiple sclerosis during systemic infections, Neurology, 67, 652, 10.1212/01.wnl.0000233834.09743.3b Sevim, 2016, Relapses in multiple sclerosis: definition, pathophysiology, features, imitators, and treatment, Turkish J. Neurol., 22, 10.4274/tnd.75318 Dutta, 2014, Relapsing and progressive forms of multiple sclerosis: insights from pathology, Curr. Opin. Neurol., 27, 271, 10.1097/WCO.0000000000000094 Cree, 2021, Secondary progressive multiple sclerosis: new insights, Neurology, 97, 378, 10.1212/WNL.0000000000012323 Nazareth, 2018, Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey, Mult. Scler. Relat. Disord., 26, 219, 10.1016/j.msard.2018.09.002 Papathanasiou, 2023, Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study, Neurol. Sci., 1 Galea, 2015, Relapse in multiple sclerosis, BMJ, 350, h1765, 10.1136/bmj.h1765 Virtanen, 2012, Viruses and multiple sclerosis, CNS Neurol. Disord. Drug Targets, 11, 528, 10.2174/187152712801661220 Helms, 2020, Neurologic features in severe SARS-CoV-2 infection, N. Engl. J. Med., 382, 2268, 10.1056/NEJMc2008597 Ismail, 2022, Association of CNS demyelination and COVID-19 infection: an updated systematic review, J. Neurol., 269, 541, 10.1007/s00415-021-10752-x Paterson, 2020, The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings, Brain, 143, 3104, 10.1093/brain/awaa240 Toscano, 2020, Guillain-Barré syndrome associated with SARS-CoV-2, N. Engl. J. Med., 382, 2574, 10.1056/NEJMc2009191 Kumar, 2020, Possible routes of SARS-CoV-2 invasion in brain: in context of neurological symptoms in COVID-19 patients, J. Neurosci. Res., 98, 2376, 10.1002/jnr.24717 Zhan, 2021, Emerging neurotropic features of SARS-CoV-2, J. Mol. Cell Biol., 13, 705, 10.1093/jmcb/mjab044 Needham, 2020, Neurological Implications of COVID-19 Infections, Neurocrit. Care, 32, 667, 10.1007/s12028-020-00978-4 Ellul, 2020, Neurological associations of COVID-19, Lancet Neurol., 19, 767, 10.1016/S1474-4422(20)30221-0 Mahalakshmi, 2021, Does COVID-19 contribute to development of neurological disease?, Immun. Inflamm. Dis., 9, 48, 10.1002/iid3.387 Arbour, 2000, Neuroinvasion by human respiratory coronaviruses, J. Virol., 74, 8913, 10.1128/JVI.74.19.8913-8921.2000 Shafiee, 2022, Epstein-Barr virus and COVID-19, J. Med. Virol., 94, 4040, 10.1002/jmv.27823 Shafiee, 2023, Reactivation of herpesviruses during COVID-19: a systematic review and meta-analysis, Rev. Med. Virol., 33, e2437, 10.1002/rmv.2437 Mahdi, 2021, COVID-19 among patients with multiple sclerosis, Neurol. Neuroimmunol. Neuroinflamm., 8, e1001, 10.1212/NXI.0000000000001001 Page, 2021, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372, n71, 10.1136/bmj.n71 Lin, 2020, Meta-analysis of proportions using generalized linear mixed models, Epidemiology, 31, 713, 10.1097/EDE.0000000000001232 Lin, 2022, Empirical Comparisons of 12 Meta-analysis Methods for Synthesizing Proportions of Binary Outcomes, J. Gen. Intern. Med., 37, 308, 10.1007/s11606-021-07098-5 Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 1088, 10.2307/2533446 Babtain, 2022, The disease course of multiple sclerosis before and during COVID-19 pandemic: a retrospective five-year study, Mult. Scler. Relat. Disord., 65, 10.1016/j.msard.2022.103985 Bsteh, 2022, Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study, Eur. J. Neurol., 10.1111/ene.15477 Conway, 2022, COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders, Mult. Scler. Relat. Disord., 63, 10.1016/j.msard.2022.103946 Czarnowska, 2021, Symptoms after covid-19 infection in individuals with multiple sclerosis in poland, J. Clin. Med., 10, 10.3390/jcm10225225 Etemadifar, 2022, Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study, BMC Neurol., 22, 64, 10.1186/s12883-022-02590-9 Etemadifar, 2021, COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect?, Mult. Scler. Relat. Disord., 51, 10.1016/j.msard.2021.102915 Garjani, 2021, COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies, Mult. Scler. Relat. Disord., 52, 10.1016/j.msard.2021.102939 Mendes, 2020, Incidence and clinical outcome of covid-19 in a cohort of 11.560 Brazilian patients with multiple sclerosis, Mult. Scler. J., 26, 95 Michelena Bustamante, 2022, Can COVID-19 exacerbate multiple sclerosis symptoms? Analysis of a case series, Mult. Scler. J., 28, NP18 Palao Rico, 2021, SARS-CoV-2 infection and multiple sclerosis: experience in Albacete (Spain), Mult. Scler. J., 27, 233 Paybast, 2023, Naser Moghadasi A. Characteristics and management of multiple sclerosis patients during the Omicron era: is there a concern about the MS course in the face of the new variant of COVID-19?, Neurolog. Sci., 44, 659, 10.1007/s10072-022-06447-4 Paybast, 2022, Naser Moghadasi A. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: a cross-sectional study in Qom province, Iran, Mult. Scler. Relat. Disord., 60, 10.1016/j.msard.2022.103712 Rahmani, 2022, COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: a case-control study, Med. Clin. Vercellino, 2023, SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: a propensity score matched case-control study, Mult. Scler. Relat. Disord., 74, 10.1016/j.msard.2023.104715 Thompson, 2018, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol., 17, 162, 10.1016/S1474-4422(17)30470-2 Steelman, 2015, Infection as an environmental trigger of multiple sclerosis disease exacerbation, Front. Immunol., 6, 520, 10.3389/fimmu.2015.00520 Nordvig, 2021, Potential neurologic manifestations of COVID-19, Neurology, 11, e135 Beghi, 2022, Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions, J. Neurol., 269, 2265, 10.1007/s00415-021-10848-4 Gupta, 2021, COVID-19 as a trigger of brain autoimmunity, ACS Chem. Neurosci., 12, 2558, 10.1021/acschemneuro.1c00403 McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann. Neurol., 50, 121, 10.1002/ana.1032 Stefanou, 2023, Safety of COVID-19 vaccines in multiple sclerosis: a systematic review and meta-analysis, Mult. Scler. J., 29, 585, 10.1177/13524585221150881 Bergvall, 2014, Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study, PLoS One, 9, e88472, 10.1371/journal.pone.0088472 Sadeghmousavi, 2020, COVID-19 and multiple sclerosis: predisposition and precautions in treatment, CCM, 2, 1802, 10.1007/s42399-020-00504-9 Kamel, 2019, Factors Involved in Relapse of Multiple Sclerosis, J. Microsc. Ultrastruct., 7, 103, 10.4103/JMAU.JMAU_59_18 AlZahrani, 2019, Association of acute stress with multiple sclerosis onset and relapse in Saudi Arabia, Saudi Med. J., 40, 372, 10.15537/smj.2019.4.24010 Sparaco, 2022, Association between relapses, stress, and depression in people with multiple sclerosis during the COVID-19 pandemic, Neurolog. Sci., 43, 2935, 10.1007/s10072-022-05917-z Yu, 2021, The effect of glucocorticoids on mortality in severe COVID-19 patients: evidence from 13 studies involving 6612 cases, Medicine (Baltimore), 100, e27373, 10.1097/MD.0000000000027373 Fischer, 2019, Glucocorticoid therapy of multiple sclerosis patients induces anti-inflammatory polarization and increased chemotaxis of monocytes, Front. Immunol., 10, 1200, 10.3389/fimmu.2019.01200 Bajafar, 2022, The impact of COVID-19 on the disease activity of multiple sclerosis: a Retrospective cohort study, Neurology, 98 Khurana, 2021, COVID-19 in multiple sclerosis: experience from North India, J. Neurol. Sci., 429, 10.1016/j.jns.2021.118164 Comabella, 2016, Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled–MS arising during Tocilizumab therapy for rheumatoid arthritis, Mult. Scler. J., 22, 257, 10.1177/1352458515623863